Real-world comparison of major bleeding and associated costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban or warfarin

被引：0
|
作者：
Amin, Alpesh [1 ]
Keshishian, Allison [2 ]
Xie, Lin [2 ]
Baser, Onur [2 ]
Price, Kwanza [2 ]
Vo, Lien [2 ]
Mardekian, Jack [2 ]
Mendoza, Mario [2 ]
Singhal, Shalabh [2 ]
Patel, Chad [2 ]
Odell, Kevin [2 ]
Trocio, Jeffrey [2 ]
机构：
[1] UC Irvine, Coll Med, Irvine, CA USA
[2] Bristol Myers Squibb, Plainsboro, NJ USA
来源：
PHARMACOTHERAPY | 2016年 / 36卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
34E
引用
收藏
页码：E214 / E214
页数：1
相关论文
共 50 条
  • [1] Real-world comparison of major bleeding and associated costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban or warfarin
    Amin, A.
    Keshishian, A. V.
    Xie, L.
    Baser, O.
    Price, K.
    Vo, L.
    Mardekian, J.
    Mendoza, M.
    Singhal, S.
    Patel, C.
    Odell, K.
    Trocio, J.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 506 - 506
  • [2] Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin
    Alpesh, Amin N.
    Keshishian, Allison
    Xie, Lin
    Baser, Onur
    Price, Kwanza
    Vo, Lien
    Singh, Prianka
    Bruno, Amanda
    Mardekian, Jack
    Tan, Wilson
    Singhal, Shalabh
    Patel, Chad
    Odell, Kevin
    Trocio, Jeffrey
    [J]. BLOOD, 2015, 126 (23)
  • [3] REAL-WORLD COMPARISON OF MAJOR BLEEDING AND ASSOCIATED COSTS AMONG ORAL ANTICOAGULANT-NAIVE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN IN THE US MEDICARE POPULATION
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Le, Hannah
    Dina, Oluwaseyi
    Qisu, Zhang
    Baser, Onur
    Vo, Lien
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 439 - 439
  • [4] REAL-WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG UNTREATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS AND THOSE INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN
    Amin, Alpesh
    Keshishian, Allison
    Xie, Lin
    Baser, Onur
    Price, Kwanza
    Vo, Lien
    Mardekian, Jack
    Mendoza, Mario
    Singhal, Shalabh
    Patel, Chad
    Odell, Kevin
    Trocio, Jeffrey
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 668 - 668
  • [5] Real-world comparisons of major bleeding risk and major bleeding-related hospitalization costs among elderly non-valvular atrial fibrillation patients newly initiated on apixaban or warfarin
    Kamble, S.
    Keshishian, A.
    Pan, X.
    Mardekian, J.
    Horbkyuk, R.
    Hamilton, M.
    Lip, G. Y. H.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 496 - 496
  • [6] Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, dabigatran, rivaroxaban or warfarin
    Lip, G. Y. H.
    Pan, X.
    Kamble, S.
    Kawabata, H.
    Mardekian, J.
    Masseria, C.
    Bruno, A.
    Phatak, H.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1085 - 1085
  • [7] Major bleeding risk in elderly patients age ≥ 75 years with non-valvular atrial fibrillation initiating oral anticoagulants: A 'real-world' comparison of warfarin, apixaban, dabigatran, or rivaroxaban
    Keshishian, Allison
    Kamble, Shital
    Pan, Xianying
    Burns, Leah
    Mardekian, Jack
    Horblyuk, Ruslan
    Hamilton, Melissa
    Squibb, Bristol-Myers
    [J]. PHARMACOTHERAPY, 2016, 36 (12): : E213 - E213
  • [8] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
    Tepper, Ping G.
    Mardekian, Jack
    Masseria, Cristina
    Phatak, Hemant
    Kamble, Shital
    Abdulsattar, Younos
    Petkun, William
    Lip, Gregory Y. H.
    [J]. PLOS ONE, 2018, 13 (11):
  • [9] Major bleeding risk in patients 75 years of age or older with non-valvular atrial fibrillation initiating oral anticoagulants: a real-world comparison of warfarin, apixaban, dabigatran, or rivaroxaban
    Lip, G. Y. H.
    Keshishian, A.
    Kamble, S.
    Pan, X.
    Burns, L.
    Mardekian, J.
    Horbkyuk, R.
    Hamilton, M.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 500 - 501
  • [10] Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin A propensity score matched analysis
    Lip, Gregory Y. H.
    Keshishian, Allison
    Kamble, Shital
    Pan, Xianying
    Mardekian, Jack
    Horblyuk, Ruslan
    Hamilton, Melissa
    [J]. THROMBOSIS AND HAEMOSTASIS, 2016, 116 (05) : 975 - 986
12345